600K GRANTgrant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to support the company's malaria vaccine program. This grant, valued at approximately $600,000 over two years, will be used to develop enhancements to the company's vectors for vaccine applications against malaria. GenVec is applying its adenovector technology to the development of malaria vaccine candidates in collaboration with the U.S. Naval Medical Research Center (
NMRC) and PATH's Malaria Vaccine Initiative. The NMRC is currently conducting a Phase I/II clinical study to assess the safety and immunogenicity of a vaccine candidate developed under this program.
RSI is overbought . MACD is still bullish but may corect very soon there is going to be a correction very soon. hopefully 1.75 will act as a support.